The Precision Bridge: MRI-Guided CED and Translatable NHP Models for CNS Drug Delivery
📅 Wednesday April 29, 2026
Accurate delivery of therapeutics to specific regions of the brain remains a central challenge in central nervous system (CNS) drug development. Limitations associated with the blood–brain barrier (BBB), as well as constraints in verifying target engagement, contribute to uncertainty during clinical translation.
This webinar introduces an integrated approach combining intraoperative MRI (iMRI)-guided navigation with Convection-Enhanced Delivery (CED) in non-human primate (NHP) models, enabling real-time visualization and controlled intracranial administration.
The session will also present image-guided dosing strategies and discuss how consistency between preclinical and clinical workflows may support more informed decision-making in CNS drug development.
Key Topics
- Challenges in CNS drug delivery and target verification
- MRI-guided intracranial procedures
- Principles and applications of Convection-Enhanced Delivery (CED)
- Integration of navigation systems for trajectory planning and real-time monitoring
- Image-guided dosing strategies in NHP models
- Improving translational continuity from preclinical to clinical stages
Who Should Attend?
This webinar may be relevant to professionals working in:
- Preclinical pharmacology and translational research
- CNS drug development in biotech companies
- Gene and cell therapies, oligonucleotide, or other biologics development
- Pharmacokinetics, biodistribution, or toxicology studies
- Neuroscience research and clinical translation
Speakers
David S. Wong
BD Manager, Asia Pacific, ClearPoint Neuro
David Wong has been the Asia Pacific Business Development Manager and on the Biologics & Drug Delivery Team at ClearPoint Neuro for 4 years. He has been working with clinical trials and regulatory projects in addition to handling commercial responsibilities in Asia, Oceania, and North America throughout his nearly 20-year career in the medical device space. Prior to that, he worked in the pharmaceutical industry. David has a master’s in biotechnology from the Johns Hopkins University.
Message Presenter 
James Song
General Manager, PRISYS Biotech
As General Manager of Prisys Biotech, James Song leverages 20 years of experience in NHP pharmacology and disease modeling to accelerate the transition from lab to clinic. He is a specialist in navigating the complexities of translational medicine, with a proven track record in managing high-value asset restructuring and forging strategic international alliances. Under his leadership, Prisys has strengthened its global footprint through sophisticated laboratory infrastructure, unique NHP models, and integrated NHP breeding operations.
Message Presenter
Register
Join this webinar to gain a structured understanding of current approaches to CNS drug delivery, including image-guided techniques and methods for evaluating biodistribution and delivery performance.
Register Now
